CAC
IONS icon

Cowen and Company’s Ionis Pharmaceuticals IONS Stock Holding History

Cowen and Company’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,700
Closed -$112K – 704
2022
Q1 		$112K Buy
13,700
+3,700
+37% +$121K 0.01% 270
2021
Q4 		$57K Sell
10,000
-10,000
-50% -$315K 0.01% 420
2021
Q3 		$53K Sell
20,000
-31,600
-61% -$1.19M ﹤0.01% 380
2021
Q2 		$28K Buy
51,600
+35,700
+225% +$1.4M ﹤0.01% 452
2021
Q1 		$210K Buy
+15,900
New +$887K 0.01% 266
2020
Q4 		– Sell
-16,500
Closed -$116K – 467
2020
Q3 		$116K Sell
16,500
-5,300
-24% -$294K 0.02% 249
2020
Q2 		$22K Sell
21,800
-5,900
-21% -$328K ﹤0.01% 336
2020
Q1 		$292K Buy
+27,700
New +$1.54M 0.07% 166

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cowen and Company's IONS Position: Q1 2024 in Review

Cowen and Company sold out of Ionis Pharmaceuticals (IONS) in Q1 2024, closing a stake of 51,415 shares — an estimated $2.6M sold.

Cowen and Company first reported a position in IONS in Q1 2020 and held it in 9 quarters. The position peaked at $2.6M in Q4 2023. 362 funds tracked by Wall St. Rank hold IONS as of Q1 2024.

  • Cowen and Company reported no remaining Ionis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 51,415 Ionis Pharmaceuticals shares in Q1 2024, an estimated $2.6M.
  • Cowen and Company first reported a position in Ionis Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Cowen and Company's Ionis Pharmaceuticals position peaked at $2.6M in Q4 2023.
  • 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.